Pharmamarketeer

Nabriva Therapeutics’ Xenleta gets US FDA approval to treat community─acquired bacterial pneumonia

Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti─infective agents to treat serious infections, announced that the US Food and Drug Administration (FDA)

Medhc-fases-banner
Advertentie(s)